{
    "nctId": "NCT05062707",
    "briefTitle": "Early Ageing During Therapy in AYA Cancer Patients",
    "officialTitle": "Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Cancer, Leukemia, Hodgkin Lymphoma, Testicular Cancer, Osteosarcoma, Ewing Sarcoma, Breast Cancer, Cervical Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 120,
    "primaryOutcomeMeasure": "Change in senescence marker P16",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18-39 years at cancer diagnosis\n* Having a histologically and/or cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.\n* Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.\n\nExclusion Criteria:\n\n* patients who are not able to understand the patient information letter and informed consent form\n* patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis\n* patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}